PubMed Health⌕ Search

Biomedical subjects

F Caracciolo

Publications and source records attributed to F Caracciolo.

At least 73 records · Page 4Linked to original sources
PubMedDate not supplied

Alternating chemotherapy regimen (P-VABEC) for intermediate and high-grade non-Hodgkin's lymphoma of the middle aged and elderly.

An intensive third generation regimen (P-VABEC) including adriamycin, etoposide, cyclophosphamide, vincristine, bleomycin and prednisolone was administered to 43 unselected elderly patients with intermediate or high-grade non-Hodgkin's lymphomas (NHL). The median age was 67, 40 per cent were Ann Arbor stage IV, 73 per cent had 'B' symptoms, 55 per cent had bulky disease, 48 per cent had serum lactate dehydrogenase greater than 450 U/l, 85 per cent had serum thymidine-kinase greater than 4 U/l. Thirty patients were previously untreated. The complete remission (CR) rate was 74 per cent, and the partial remission (PR) rate 23 per cent, with an overall response rate of 97 per cent. The regimen was carried out on an outpatient basis in all patients. No death occurred during therapy. The Kaplan-Meier actuarial survival of all patients at 3-years is 47 per cent, and 50 per cent (16/32) of all patients who attained CR remain alive and in remission at a median of 21+ months (range 6+ to 42+). These results confirm that high remission and failure-free survival rates can be achieved also in elderly unselected patients with aggressive NHL treated with curative intent.

Aged↗
PubMedDate not supplied

High efficacy of Rituximab in indolent HCV-related lymphoproliferative disorders associated with systemic autoimmune diseases.

OBJECTIVE: The evidence of an increased frequency of B-non Hodgkin's lymphomas (NHL) in patients with HCV and systemic autoimmune diseases suggests a close relationship between infection, autoimmunity and cancer. Choosing the best therapy for patients affected either by HCV-related lymphoma or autoimmune disorders is not easy; in fact, some treatments may be accompanied by an excessive hepatic toxicity and may be followed by a reactivation of hepatitis. There is growing interest in the search for an ideal therapy for this kind of patient. Thanks to its mechanism of action and good toxicity profile, Rituximab could prove to be an attractive therapeutic option: it has been reported to be highly active in low-grade NHLs and has been proposed for the management of autoimmune diseases. RESULTS: In this paper we evaluate the role of anti-CD20 monoclonal antibody in mono-therapy in 10 patients with either indolent HCV-related lymphoma or autoimmune disease. A very high rate of response, of both NHL and of the associated autoimmune disease, was observed (100% of clinical response), with no significant hepatic and extra-hepatic toxicity. CONCLUSION: Thus, although the number of patients was small, our data strongly support the use of anti-CD20 in this patient setting.

Adult↗
PubMedDate not supplied

Low-dose ARA-C and 1(OH) D3 administration in acute non lymphoid leukemia: pilot study.

BACKGROUND AND METHODS: Vitamin D3 metabolites have been shown to be able to induce monocytic differentiation both in vitro and in vivo. In this paper we report the preliminary results of an uncontrolled clinical trial where low doses of ARA-C and 1(OH)D3 were administered to patients affected by acute non lymphoid leukemia. The achievement of complete or partial remission was recorded. Morphological and cytochemical studies were performed in order to control the blastic populations under therapy. Immunocytochemical studies were also performed in some patients in order to detect the presence of 1,25(OH)2D3 receptors in the blast population. Seventeen percent reached complete remission and 45% reached only a partial remission. RESULTS AND CONCLUSIONS: The results are in line with those showing that low doses of ARA-C are an effective treatment in this type of leukemia. In some cases (7/11), a monocytic/monoblastic shift was detected. The demonstration of 1,25(OH)2D3 receptors in some blasts is also reported. Thus it is possible to suggest that the vitamin D metabolite displays "in vivo" the differentiating activity already shown "in vitro".

Adult↗
PubMedDate not supplied

P-glycoprotein and drug resistance in acute leukemias and in the blastic crisis of chronic myeloid leukemia.

The aim of this work is to evaluate the relationship between P-glycoprotein expression in circulating blasts and clinical response in patients suffering from acute lymphoblastic leukemia, acute non-lymphoblastic leukemia, and chronic myeloid leukemia in either lymphoid or myeloid blastic crisis. The results obtained show that: a) patients whose blasts express P-glycoprotein are resistant towards protocols including Doxorubicin, Daunorubicin, Etoposide, Mithramycin, Vincristine; b) P-glycoprotein can be expressed constitutively in some cases; c) P-glycoprotein does not appear to be the only mechanism responsible for resistance towards anthracyclines and Etoposide.

ATP Binding Cassette Transporter, Subfamily B, Mem↗
PubMedDate not supplied

Automatic differential blood counting in plasma cell leukemia.

The authors report a case of primary plasma cell leukemia and two cases of multiple myeloma with a large number of circulating plasma cells. The display of Technicon H-1 shows a very high "cloud" in the area of large unstained cells. A massive invasion of the basophil area was not found. Differences between these results and those found in different lymphoid leukemias are discussed.

Aged↗
PubMedDate not supplied

[P-glycoprotein and treatment with plicamycin + hydroxyurea in myeloid blastic crisis of chronic myeloid leukemia].

The authors studied P-glycoprotein (P-gp) expression in three patients affected by myeloid blast crisis of chronic myeloid leukemia undergoing chemotherapy with plicamycin + hydroxyurea. P-gp is the molecular marker of multidrug resistance (MDR), and is able to promote the efflux of various drugs (including plicamycin) from the neoplastic cell. When resistance towards plicamycin and hydroxyurea association was observed, the blasts obtained from the three patients were found to express P-gp. Although P-gp may be not the unique mechanism responsible for resistance towards plicamycin and hydroxyurea association, the MDR phenotype may play an important role in the resistance towards this treatment protocol in the blast crisis of chronic myeloid leukemia.

ATP Binding Cassette Transporter, Subfamily B, Mem↗